Company Profile
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company provides the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic.
Its portfolio also includes RAD102, a pivalate therapeutic, RAD201a, a Nano-mAb HER-2 breast diagnostic, RAD202, a Nano-mAb HER-2 breast therapeutic, RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic, and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products.
Its portfolio also includes RAD401, a PSA-mAb prostate cancer diagnostic, RAD402, a PSA-mAb prostate cancer therapeutic, RAD601, a PTPµ glioblastoma diagnostic, and RAD602, a PTPµ glioblastoma therapeutic.
The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.